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Abstract
Background:  Vascular endothelial growth factor receptor-2 (VEGFR-2, KDR), a receptor
tyrosine kinase, regulates mitogenic, chemotactic, hyperpermeability, and survival signals in vascular
endothelial cells in response to its ligand vascular permeability factor/ vascular endothelial growth
factor (VPF/VEGF). SHP-1 is a protein tyrosine phosphatase known to negatively regulate signaling
from receptors such as EGF receptor, IL3 receptor, erythropoietin receptor and also KDR.
However, the mechanism by which SHP-1 executes KDR dephosphorylation, the targeted tyrosine
residue(s) of KDR and also overall downstream signaling or phenotypic change(s) caused, is not
defined.
Results: Here, we have demonstrated that KDR and SHP-1 are constitutively associated and upon
VEGF treatment, the phosphatase activity of SHP-1 is stimulated in a c-Src kinase dependent
manner. Knockdown of SHP-1 by siRNA or inhibition of c-Src by an inhibitor, results in augmented
DNA synthesis perhaps due to increased phosphorylation of at least three tyrosine residues of
KDR 996, 1059 and 1175. On the other hand, neither tyrosine residue 951 of KDR nor VEGF-
mediated migration is affected by modulation of SHP-1 function.
Conclusion: Taken together our results define the tyrosine residues of KDR that are regulated
by SHP-1 and also elucidates a novel feed back loop where SHP-1 is activated upon VEGF treatment
through c-Src and controls KDR induced DNA synthesis, eventually leading to controlled
angiogenesis.
Background
Angiogenesis, the sprouting of new blood vessels from
pre-existing endothelium is a fundamental feature of both
normal physiology and pathologic states including coro-
nary heart disease, diabetes, retinopathy and cancer [1-4].
The growth factor VEGF-A is a key regulator of physiologic
and pathologic angiogenesis [5]. VEGF was identified due
to its ability to induce vascular hyperpermeability but has
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since been recognized as a potent inducer of endothelial
proliferation, migration and survival. VEGF also acts as a
proinflammatory cytokine and induces the expression of
a number of molecules implicated in regulating angiogen-
esis [6,7].
The effects of VEGF and its family of proteins are mediated
by three structurally related receptor tyrosine kinases
namely VEGFR1/Flt-1, VEGFR-2/Flk-1/KDR, VEGFR3/Flt-
4 [8-12]. Among these, KDR has emerged as the main
receptor mediating VEGF effects such as endothelial cell
proliferation, migration and proinflammatory activation.
In contrast, Flt-1 is thought to mediate inhibitory and/or
decoy effects in endothelial cells [13,14]. Flt-4 is mainly
expressed in lymphatics and regulates lymphangiogenesis
[12]. The importance of VEGF/KDR axis is accentuated by
the fact that increased levels of both ligand and receptor
are found in tumor cells as well as stroma [15-19].
Src homology 2 (SH2) domain-containing protein tyro-
sine phosphatase (SHP) -1 and -2 are non-receptor pro-
tein tyrosine phosphatases (PTPs). Expression of SHP-1 is
restricted to hematopoietic cells whereas SHP-2 is more
widely expressed [20]. SHP-1 has been proposed to be a
candidate tumor suppressor gene in lymphoma, leukae-
mia and other cancers [21]. Evidence for the differing
roles of SHP-1 and SHP-2 in cell signaling has come from
the study of mice lacking functional SHP-1 or SHP-2. The
SHP-1 gene mutated motheaten (me) mice display severe
haematopoietic disruption with chronic inflammation
and systemic autoimmunity and die from hemorrhagic
pneumonitis [22,23]. Thus the results provide strong evi-
dence for a major role of this phosphatase in the negative
regulation of cell function. Targeted disruption of the
SHP-2 gene results in embryonic lethality of homozygous
mutant mice however generation of chimeric mice from
homozygous SHP-2 mutant ES cells and wild-type
embryos determined a role for SHP-2 in blood cell devel-
opment [24,25]. Other studies have demonstrated a role
for SHP-2 in positively regulating signaling downstream
of the insulin receptor, platelet derived growth factor
receptor (PDGFR) and fibroblast growth factor receptor
(FGFR) (reviewed in [26]. The SHP-1 enzyme contains
two tandem SH2 domains at the N-terminus, followed by
the catalytic domain and a C-terminal tail. The C-terminal
tail contains multiple sites of tyrosine and serine phos-
phorylation and this part of the protein has been pro-
posed to have an important regulatory function [20].
A number of studies have shown that SHP-1 negatively
regulates signaling of receptors such as the EGF receptor,
IL3 receptor, erythropoietin receptor and KDR [27-29].
Studies have also suggested that SHP-1 is a negative regu-
lator of angiogenesis in vivo because SHP-1 deficient mice
are resistant to TIMP-2 inhibition [30]. SHP-1 has also
been shown to co-precipitate with KDR upon stimulation
with VEGF and overexpression of SHP-1 resulted in
impairment of VEGF mediated KDR autophosphorylation
and ERK activation [29]. However, the signaling mecha-
nism by which this inhibition takes place remains to be
elucidated. Here, we have clearly defined the respective
tyrosine residues of KDR that are regulated by SHP-1 and
hence affect downstream signaling. We have also demon-
strated that KDR and SHP-1 are constitutively associated
and upon VEGF treatment the phosphatase activity of
SHP-1 is stimulated in a c-Src kinase dependent manner.
Tyrosine phosphorylation and activation of SHP-1 is reg-
ulated by c-Src. Knockdown of SHP-1 by siRNA or inhibi-
tion of c-Src results in amplified proliferation that may be
due to increased phosphorylation of at least three tyrosine
residues on KDR such as 996, 1059 [31] and 1175 [32].
Interestingly, VEGF-mediated migration is not affected as
well as tyrosine residue 951 on KDR is unchanged [31].
Overall, our results define the residues on KDR that are
regulated by SHP-1 and also elucidate a novel feed back
loop by which SHP-1 is activated upon VEGF treatment
through c-Src kinase and attenuates KDR mediated DNA
synthesis.
Results
SHP-1 Co-Precipitates with KDR and Src
Initially, co-precipitation studies were carried out to deter-
mine the role of SHP-1 in KDR mediated signaling. As
shown in Fig 1A, we observed that KDR co-immunopre-
cipitated with SHP-1 in HUVEC with or without VEGF
treatment. The specificity of the SHP-1 antibody was
determined using the catch and release column (see Addi-
tional file 1). Our results are in contrast to two previous
reports that suggest the association of SHP-1 with KDR
upon induction with VEGF [33,34]. However, we have
repeatedly found constitutive association between KDR
and SHP-1. We have speculated that the association of
SHP-1 with KDR occurs through the SH2 domains of
SHP-1 but activation of the phosphatase activity occurs
only when VEGF treatment causes availability of phos-
phorylated residues on KDR. KDR also co-immunoprecip-
itated with c-Src kinase in HUVEC treated with or without
VEGF (Fig 1B). Interestingly, the association of KDR with
c-Src significantly increased upon treatment with VEGF.
Next, we addressed the question whether VEGF treatment
could increase the phosphatase activity of SHP-1 and how
c-Src kinase influences this activation?
Activation of SHP-1 Upon VEGF Stimulation
It has been previously established that the catalytic activ-
ity of SHP-1 is regulated by the phosphorylation of amino
acids at the C terminus of the protein [20]. The phos-
phatase activity of SHP-1 is increased by phosphorylation
on Tyr 536 and decreased by phosphorylation on Ser 591.
Similarly, we observed that upon stimulation of HUVECJournal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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with VEGF, tyrosine phosphorylation of SHP-1 increased
whereas serine phosphorylation decreased (Fig 2A,B). The
increase in tyrosine phosphorylation and decrease in ser-
ine phosphorylation suggested that the phosphatase activ-
ity of SHP-1 was activated upon VEGF stimulation. When
we utilized PP2, a c-Src kinase inhibitor, VEGF mediated
tyrosine phosphoryation of SHP-1 was inhibited (Fig 2B)
but not with PP3, the analog of PP2. It should be noted
that upon PP2 treatment overall phosphorylation of tyro-
sine residues on KDR also increased compared to the con-
trol. These results suggested that c-Src might play a role in
VEGF-mediated SHP-1 phosphatase activation by phos-
phorylating its tyrosine residue.
Next we examined the status of phosphatase activity of
SHP-1 in HUVEC in response to VEGF treatment. As
shown in Figure 3, phosphatase activity of SHP-1 (data
normalized with respect to negative control) significantly
increased after VEGF treatment and decreased after treat-
ment with PP2 but not with PP3. That equal amounts of
SHP-1 and not SHP-2 protein immunoprecipitated with
the different treatments was also confirmed (Fig 3 and see
Additional file 1). We also performed a time course study
(0, 5, 15, 30 and 60 min) but did not observe any signifi-
cant increase in the phosphatase activity of SHP-1 over
control beyond 5 min treatment with VEGF (data not
shown). However, the question remains why VEGF treat-
ment promotes SHP-1 phosphatase activity? Hence, we
postulated that in the absence of SHP-1 we should
observe an increase in VEGF mediated signaling in EC.
SHP-1 is Required for Modulating the VEGF-Mediated 
DNA Synthesis
Herein, we utilized SHP-1 siRNA to block its expression in
HUVEC. The image quantitation data indicate that there
was a ~80% decrease in protein levels of SHP-1 after 48
hrs in HUVEC transfected with SHP-1 siRNA as compared
to that of scrambled siRNA. The SHP-1 siRNA was specific
since there was no change in SHP-2 protein levels (Fig
4A). We further studied VEGF-mediated DNA synthesis in
HUVEC in response to 10 ng/ml VEGF by [3H]thymidine
incorporation after transfection with SHP-1 siRNA. Inter-
estingly, Figure 4B shows that there was a significant and
consistent increase in [3H]thymidine incorporation by
HUVEC when treated with VEGF suggesting further that in
the presence of VEGF, SHP-1 functions as an active phos-
phatase.
Knockdown of SHP-1 Interferes With VEGF Induced 
Signaling
To examine further the signaling components in the pro-
liferation pathways, we examined phospho-KDR as an
upstream marker and phospho-ERK as a downstream
marker. It has been shown previously that tyrosine resi-
dues 996, 1059 and 1175 are phosphoryted in the pres-
ence of VEGF and lead to EC proliferation [31,32]. In
HUVEC transfected with SHP-1 siRNA, phosphorylation
of KDR at Tyr996, 1059 and 1175 increased significantly
(Image quantitation data, Additional file 2) as compared
to that of scramled siRNA, when treated with VEGF (Fig
5A). However, there is no significant difference in the
phosphorylation of KDR at Tyr951 (Fig 5A) (Image quan-
titation data, see Additional file 2). In addition, no signif-
icant difference in migration was observed between
scrambled control and SHP-1 siRNA treated HUVEC in
KDR, c-Src and SHP-1 co-precipitate and are part of one  complex Figure 1
KDR, c-Src and SHP-1 co-precipitate and are part of 
one complex. (A) Serum starved HUVEC was treated with 
or without VEGF 10 ng/ml for 5 min and immunoprecipitated 
with antibody against KDR and immunoblotted with SHP-1 
antibody. The first lane represents negative control (rabbit 
IgG). (B) Serum starved HUVEC was treated with or without 
VEGF 10 ng/ml for 5 min and immunoprecipitated with anti-
body against c-Src and immunoblotted with KDR and Src 
antibody.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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the presence of VEGF suggesting that SHP-1 might not
influence VEGF-mediated migration (Fig 6 and see Addi-
tional file 4). We next performed a time course study,
0–60 min, on siRNA transfected HUVEC treated with
VEGF. We observed a significant increase in phosphoryla-
tion of ERK and in Tyr1175 residue of KDR in SHP-1
siRNA treated HUVEC compared to the scrambled control
(Fig 5B), but only in the 5 min treatment window (Image
quantitation data, see Additional file 3). Collectively,
these data suggest that SHP-1 modulates some specific
tyrosine residues of KDR that ultimately influences VEGF
mediated DNA synthesis, but not migration.
Modulation of KDR Phosphorylation and DNA Synthesis 
by c-Src
We next examined whether inhibition of c-Src kinase in
VEGF-induced EC also mimics tyrosine phosphoryation
of specific KDR residues as well as increased DNA synthe-
sis. Accordingly, HUVEC were treated with c-Src kinase
inhibitor PP2 and its analog PP3 at a dose of 5 uM in the
presence or absence of VEGF 10 ng/ml. Figure 7A clearly
shows that phosphorylation of Tyr 996, 1059 and 1175
residues of KDR increased upon treatment with PP2 in the
presence of VEGF whereas PP3 was unable to do the same
(Image quantitation data, see Additional file 5). We also
observed a significant increase in ERK phosphorylation
and proliferation of HUVEC both in the presence and
absence of VEGF as compared to that of controls upon
treatment with PP2 at a dose of 5 uM but not when treated
with PP3 (Fig 7B and see Additional file 6). Confocal
microscopy experiments also revealed an increase in
phospho Tyr996 staining of KDR upon treatment with
VEGF and a further increase in membrane staining upon
PP2 treatment (Fig 8C, 8F). This pattern was not observed
with bFGF treatment (Fig 8D) or in cells without VEGF
(Fig 8B) and specificity of the antibody was determined by
Serine and tyrosine phosphorylation of SHP-1 Figure 2
Serine and tyrosine phosphorylation of SHP-1. (A) Serum starved HUVEC was treated with or without VEGF 10 ng/ml 
for 5 min and immunoprecipitated with antibody against phospho-Ser and immunoblotted with HRP conjugated SHP-1 anti-
body. (B) Serum starved HUVEC was pretreated with PP2 or PP3, 5 uM for 1 h followed by treatment with VEGF 10 ng/ml for 
5 min and immunoprecipitated with antibody against phospho-Tyr and immunoblotted with SHP-1 and KDR antibody. Cell 
lysates from the same sample were also run to show total KDR levels.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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staining with the boiled antibody (Fig 8A). Overall, the c-
Src kinase inhibition data clearly corroborate the results
obtained with SHP-1 siRNA transfection and support our
hypothesis that c-Src, upon activation by VEGF activates
SHP-1 phosphatase activity and therefore regulates KDR
function.
Modulation of KDR Phosphorylation by SHP-1 Tyrosine 
Mutants
To determine the target tyrosine residues on KDR that
could be dephosphorylated by SHP-1, we next overex-
pressed wild-type (WT) or the respective tyrosine mutants
of SHP-1, namely, Y538, Y543 and Y566 in HUVEC. Over-
expression was confirmed by western blot (Fig 9A). We
observed that compared to the control cells stimulated
with VEGF, phosphorylation of both Tyr1059 and
Tyr1175 on KDR decreased in cells expressing the WT pro-
tein and increased significantly in cells expressing Y538
mutant SHP-1 protein (Fig 9B,9C). The other SHP-1
mutants such as Y543 or Y566 did not significantly mod-
ulate tyrosine phosphorylation of KDR. Therefore we infer
that Y538 on SHP-1 is essential for dephosphorylation of
tyrosine residues on KDR following VEGF stimulation.
Discussion
VEGF is a critical regulator of angiogenesis, primarily
through the signaling mediated by KDR. Although the sig-
naling pathways via KDR have been extensively studied,
the role of key proteins that modulate and 'fine-tune'
VEGF signaling remains to be elucidated. In the present
study, we have defined the specific tyrosine residues on
KDR that are dephosphorylated by SHP-1 and modulate
VEGF-mediated signaling. We also show that this dephos-
phorylation of tyrosine residues on KDR occurs upon
stimulation with VEGF resulting in the activation of c-Src
kinase and tyrosine phosphorylation of SHP-1. Our
results are supported by the fact that the inhibition of c-
Src kinase resulted in increased immunostaining of phos-
pho-KDR with a concomitant increase in HUVEC prolifer-
ation and pERK. Our data clarifies a previously
unexplained increase in phospho-KDR levels upon treat-
ment with PP2 as described by Labrecque et al [35].
SHP-1 and KDR and KDR and c-Src co-immunoprecipi-
tated with each other and the association between SHP-1
and KDR remained unchanged with or without VEGF
treatment. Prior studies have indicated that VEGF induces
association of SHP-1 with KDR. However our data consist-
ently suggested that SHP-1 associates with KDR regardless
of VEGF treatment. We presumed that in the culture con-
ditions even after overnight starvation KDR remains phos-
phorylated at low levels leading to association with SHP-
1. More importantly our data suggest that it is perhaps not
the association but the activation of the tyrosine phos-
phatase activity of SHP-1 that is critical in regulating KDR-
mediated downstream signaling. Nonetheless, the associ-
ation of KDR with c-Src increased upon treatment with
VEGF in HUVEC. Our results are in complete accordance
with prior studies that have reported preferential associa-
tion of c-Src with KDR upon stimulation with VEGF [36].
Knockdown of SHP-1 by siRNA in HUVEC caused a signif-
icant and consistent increase in proliferation after treat-
ment with VEGF. These results suggest that the
phosphatase activity of SHP-1 potentiates upon VEGF
treatment. Previous reports suggested that the activity of
SHP-1 is regulated by phosphorylation of the tyrosine and
serine residues in the C terminus of the protein [20]. SHP-
1 is phosphorylated on serine residues, constitutively in
resting murine T cells. In human platelets it is phosphor-
ylated on both tyrosine and serine residues in response to
thrombin [37]. This is PKC dependent and correlates with
an increase in the activity of SHP-1. In platelets, PKCα is
constitutively bound to SHP-1 and PKCα dependent ser-
ine phosphorylation at 591 led to a decrease in phos-
phatase activity. However our results suggest that serine
phosphorylation of SHP-1 decreases upon VEGF stimula-
tion. SHP-1 is also phosphorylated on Tyr536 by the insu-
lin receptor tyrosine kinase and this induces activation of
SHP-1 phosphatase assay Figure 3
SHP-1 phosphatase assay. Phosphatase assay was per-
formed using pNNP. Serum starved HUVEC was pretreated 
with PP2 or PP3, 5 uM for 1 h followed by treatment with 
VEGF 10 ng/ml for 5 min and immunoprecipitated with anti-
body against SHP-1 using, "catch and release column," from 
Upstate. One part was run on a gel and the other part was 
used for the phosphatase assay. Data represent average of 
three independent determinations normalized with respect 
to negative control (P = 0.001).Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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its phosphatase activity [38]. A recent report by Frank et
al., showed that c-Src is able to tyrosine phosphorylate
SHP-1 in vitro, leading to an increase in the activity of the
phosphatase [39]. Phosphorylation of SHP-1 at tyrosine
538 was required for optimal phosphatase activity of SHP-
1 [39]. Therefore our observation of increased KDR phos-
phorylation upon mutation of Y538 of SHP-1 compared
to the control in VEGF stimulated cells is substantiated by
the previous reports. We also observed an increased c-Src
dependent tyrosine phosphorylation of SHP-1 and inhibi-
tion of c-Src kinase activity by PP2 caused a significant
increase in DNA synthesis as well as phospho-KDR
(Y996) staining on HUVEC. It should be mentioned here
that the relative increase in DNA synthesis after inhibiting
c-Src kinase compared to knockdown of SHP-1 was much
more potent. This is probably because c-Src negatively reg-
ulates a number of other proteins including caveolin-1
and dynamin that may play a role in proliferation [35,40].
We also identified specific tyrosine residues on KDR that
were phosphorylated more in SHP-1 knockdown and PP2
treated cells. Migration, as determined by the wound heal-
ing assay or phospho-KDR (Y951) a marker for migration,
was not significantly affected while proliferation markers
like phospho-Y996, Y1059 and Y1175 were significantly
more phosphorylated. An increase in phospho-ERK was
also observed in SHP-1 siRNA treated cells. This finding is
Knockdown of SHP-1 using siRNA and its effect on DNA synthesis Figure 4
Knockdown of SHP-1 using siRNA and its effect on DNA synthesis. (A) HUVEC were transfected with scrambled 
control or SHP-1 siRNA using oligofectamine and protein levels checked after 48 h. β actin served as a loading control. SHP-2 
levels were not affected. NIH Image quantitation data normalized with respect to b actin is shown. (B) HUVEC were trans-
fected with scrambled control or SHP-1 siRNA using oligofectamine. After 48 h, the cells were plated on 24 well plates and 
[3H]thymidine incorporation assay carried out as described in Materials and Methods. Data represent average of five independ-
ent determinations each in triplicate (P = 0.004).Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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supported by a previous study that showed activation of
ERK1/2 after using a dominant-negative inhibitor of SHP-
1 [41].
It has been previously shown that in 293T cells Tyr996 of
KDR perhaps remains phosphorylated as no difference is
observed in the phosphopeptide map after addition of
VEGF (12). However, in our experiments we repeatedly
find Tyr996 of KDR to be phosphorylated in a VEGF
dependant manner. This has been confirmed by Western
blotting as well as confocal microscopy. We also con-
firmed specificity of the antibody by staining with or with-
out bFGF treatment. We found clear, distinct membrane
staining after treatment with VEGF but not bFGF. This
leads us to speculate that HUVEC being endothelial cells
differ from 293T in the way they respond to VEGF or that
Tyr996 might not be autophosphorylated and could be
phosphorylated by some other kinase upon activation
with VEGF.
However, the question remains why SHP-1 with the help
of c-Src kinase controls KDR-mediated proliferation in
Effect of SHP-1 knockdown on phosphorylation of KDR and ERK Figure 5
Effect of SHP-1 knockdown on phosphorylation of KDR and ERK. (A) HUVEC were transfected with scrambled con-
trol or SHP-1 siRNA using oligofectamine. After 48 h the cells were serum starved and treated with or without VEGF 10 ng/ml 
and immunoblotted with antibodies against p-Tyr of KDR. Total KDR served as a loading control. (B) HUVEC were trans-
fected with scrambled control or SHP-1 siRNA using oligofectamine. After 48 h the cells were serum starved and treated with 
or without VEGF 10 ng/ml and immunoblotted with antibodies against p-ERK. Total ERK served as a loading control.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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HUVEC. In order for proper vascular remodeling to occur,
fine-tuning of proliferative and/or anti-proliferative cues
controlling KDR-induced downstream signaling is
expected to be required and with VEGF as a potential
endothelial mitogen, it is a logical candidate. In this
regard, other than its role in vascular hyperpermeability
[42], VEGF-mediated c-Src kinase activation, leads to a
better organization of vascular structure by controlling
KDR function. Future studies are in progress to resolve the
current hypothesis. Nonetheless, our study illustrates a
new role for c-Src as well as SHP-1 in VEGF-induced ang-
iogenesis.
Conclusion
The main conclusions are: 1. KDR, SHP-1 and c-Src are
part of the same immnocomplex. 2. The phosphatase
activity of SHP-1 increases after VEGF treatment and is Src
dependent. 3. Inhibition of Src in endothelial cells causes
increased tyrosine phosphorylation of VEGFR-2 and pERK
ultimately leading to increased proliferation. 4. We iden-
tified the specific tyrosine residues on KDR that are mod-
ulated by SHP-1. 5. We identified Y538 on SHP-1 to be the
major site that regulates its phosphatase activity and
hence is responsible for de-phosphorylation of tyrosine
residues on VEGFR-2 subsequent to VEGF stimulation.
Methods
Reagents
VEGF-A was obtained from R&D systems, Minneapolis,
MN. [3H] Thymidine was from Amersham Biosciences.
The antibodies to KDR, c-Src, phosphoKDR (996) and
phosphoKDR (951) were from Santa Cruz Biotechnology
(Santa Cruz, CA); phosphoKDR (1059) was from Upstate
and phospho KDR (1175) from Cell Signaling. PP2 and
PP3 were from EMD Biosciences (San Diego, CA). The
antibodies to SHP-1 were from Santa Cruz Biotechnology
(Santa Cruz, CA) and BD-Biosciences (San Jose, CA).
Immunoflourescence
Anti-KDR monoclonal antibody used for immunofloures-
cence was from Sigma-Aldrich, St. Louis, MS. AlexaFlour
488 anti-mouse or AlexaFlour 546 anti-rabbit secondary
antibody was from Molecular probes, Eugene, OR. 2 × 104
HUVEC were seeded on collagen coated Lab-Tek chamber
slides. After 24 h cells were serum starved. The next day
cells were treated with or without VEGF 10 ng/ml. Slides
were washed in PBS, fixed in 4% paraformaldehyde (PFA)
and permeabilized with 0.2% TRITON X-100 at room
temperature. Slides were washed in PBS, blocked in 10%
goat serum and stained with respective primary antibod-
ies in 1% goat serum for 2 hrs. Slides were washed in PBS
and incubated for 1 h in respective secondary antibody at
a dilution of 1:200 followed by post-fixing in 4% PFA and
mounting in Vectashield, Vector Labs, CA. Confocal
microscopy was performed using a Zeiss LSM 510 confo-
cal laser scan microscope with C-Apochromat 63×/NA 1.2
water-immersion lens. Absence of signal crossover was
established using single-labeled samples.
Immunoprecipitation and Western Blot Analysis
Serum starved HUVEC were treated with or without VEGF
10 ng/ml and/or PP2 or PP3 5 uM. Cell lysates in RIPA
buffer supplemented with protease inhibitor cocktail were
prepared from HUVEC. The lysates were collected after
centrifugation at 14000 × g for 10 min at 4°C. 500 ug of
lysate protein was incubated with 1 mg respective anti-
body for 1 h and 50 ml of proteinA/G-conjugated agarose-
beads for an additional hour at 4°C. Beads were washed
with RIPA buffer three times and immunoprecipitates
were resuspended in 2× SDS sample buffer.
HUVEC were transfected with the following plasmids con-
trol pCDNA (C) or SHP-1 wildtype (WT) or SHP-1 Y538
or SHP-1 Y543 or SHP-1 Y566 mutants using nucleofector
based electroporation. The above plasmids were a kind
gift from Dr. Z. Yu (National Research Council, Canada).
After 48 hrs. the cells were starved overnight in EBM
medium without serum. Subsequently the cells were stim-
ulated with VEGF 10 ng/ml for 5 min. Cell lysates were
collected and immunoblotted with respective antibodies.
Please note that immunoprecipitation or western blot as
shown in Fig. 1 through Fig. 5 was performed exactly as
described here but without any overexpression of SHP-1,
KDR or Src rather on endogenous proteins from HUVEC
lysates. Experiments were repeated at least three times.
Effect of SHP-1 knockdown on migration Figure 6
Effect of SHP-1 knockdown on migration. HUVEC 
were transfected with scrambled control or SHP-1 siRNA 
using oligofectamine. After 48 h, the cells were plated on 6 
well plates and wound healing migration carried out as 
described in Materials and Methods. Data represent average 
of three independent determinations each in triplicate.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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Cell Proliferation Assay
HUVECs (2 × 104) were seeded in 24-well plates and cul-
tured for 24 h in EGM. After 24 h the cells were serum
starved and pre-treated with or without PP2 or PP3 at 5
mM for 1 h respectively before stimulation with VEGF 10
ng/ml. After culture for 20 h, 1 mCi of [3H]thymidine was
added to each well; 4 hrs later, cells were washed with
chilled PBS, fixed with 100% cold methanol and collected
for measurement of trichloroacetic acid-precipitable radi-
oactivity. Experiments were repeated at least three times
each time in triplicate.
siRNA Transfection
1 × 105 HUVEC were seeded in 60 mm plates and cultured
for 24 h in EGM. The next day cells were washed with
OPTI-MEM reduced serum medium and transfected with
50 nM SHP-1 siRNA obtained from Santa Cruz Biotech-
nology (sc29478) using oligofectamine (Invitrogen). This
siRNA is a pool of 3 sequences. Sense Strand (A):CUG-
GUGGAGCAUUUCAAGATT, (B):CGCAGUACAAGUU-
CAUCUATT and (C): CAACCCUUCUCCUCUUGUATT.
After 4 hrs antibiotic free EGM was added and cell lysates
were prepared 48 hrs after transfection.
Effect of inhibition of c-Src on phospho-Tyr of KDR and DNA synthesis Figure 7
Effect of inhibition of c-Src on phospho-Tyr of KDR and DNA synthesis. (A) HUVEC was pretreated with PP2 or PP3 
at 2.5 or 5 uM for 1 h and then with or without VEGF 10 ng/ml and immunoblotted with antibodies against p-Tyr of KDR. 
Total KDR served as loading control. (B) HUVEC were plated in 24 well plates, pretreated with PP2 or PP3 at 5 uM for 1 h and 
then with or without VEGF 10 ng/ml and [3H]thymidine incorporation carried out as described in Materials and Methods. 
Another set of the same treatment was subjected to a western blot for pERK and total ERK. Data represent average of three 
independent determinations each in triplicate (P = 0.03).Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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SHP-1 Phosphatase Assay
Phosphatase assay was performed according to manufac-
turers protocol (Stratagene, Signal Scout Phasphatase Pro-
filing System). Briefly, HUVEC were pretreated for 1 h
with 5 mm PP2 or PP3 and then with or without 10 ng/
ml VEGF for 5 min. Cells were lysed (100 mM NaCl, 10
mM Tris-HCl pH 8.0, 1 mM EDTA, 1% Triton ×, 5 mM
DTT), lysate pre-cleared and protein quantity determined
by Bradford assay. Equal amount of protein from each
sample was then immunoprecipitated with a SHP-1 anti-
body using the "catch and release column" from Upstate.
One part was then subjected to western blot and another
part was treated as follows; 80 ul complete assay buffer
(14 mM HEPES pH 7.4, 30 mM NaCl, 1.5 mM EDTA, 5
mM DTT) was added and eluted from the column. 120 ul
pNPP substrate (20 mM) was then added to each sample
and absorbance at 405 nm was read after 30 min incuba-
tion at 30°C on a TECAN Spectra Flour Plus. Data pre-
sented were normalized with respect to negative control.
Three independent experiments were performed.
Wound Healing Migration
Monolayers of HUVEC transfected with scrambled con-
trol or SHP-1 siRNA were scratched with a universal blue
pipette tip and incubated for 12 hrs in the presence of 10
ng/ml VEGF. Thymidine (10 mM; Sigma-Aldrich) was
included during the incubation to inhibit cell prolifera-
tion. Migration of cells across the scratched area was
recorded by time-lapse microscopy (Apotome, Carl Zeiss)
using AXIO Vision software. Cells were counted from five
fields per well.
Localization of p-Tyr 996 of KDR Figure 8
Localization of p-Tyr 996 of KDR. (A) HUVEC was treated with VEGF 10 ng/ml for 5 min and then stained with boiled p-
Tyr 996 KDR antibody, this served as a negative control. (B) Untreated HUVEC was stained with p-Tyr 996 KDR antibody in 
red. (C) HUVEC treated with VEGF 10 ng/ml for 5 min was stained with p-Tyr 996 KDR antibody in red. (D) HUVEC was 
treated with bFGF 20 ng/ml and then stained with p-Tyr 996 KDR antibody in red. (E) HUVEC was pretreated with PP2 at 5 
mM for 1 h and then stained with p-Tyr 996 KDR antibody in red. (F) HUVEC was pretreated with PP2 at 5 mM for 1 h and 
then with VEGF 10 ng/ml for 5 min and stained with p-Tyr 996 KDR antibody in red. The nuclei of the cells are stained with 
DAPI and appear blue. Magnification of images is noted in the lower right corner.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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Statistical Analysis
All values are expressed as means ± SD. Statistical signifi-
cance was determined using two-sided Student's t test,
and a value of P < 0.05 was considered significant. For Fig-
ure 5B, ANOVA was calculated using Tukey's Studentized
Range (HSD) Test. Comparisons significant at the 0.05
level are shown (Supplemental data).
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Effect of SHP-1 mutations on de-phosphorylation of tyrosine residues on KDR Figure 9
Effect of SHP-1 mutations on de-phosphorylation of tyrosine residues on KDR. (A) HUVEC was transfected with 
the following plasmids control pCDNA (C) or SHP-1 wildtype (WT) or SHP-1 Y538 or SHP-1 Y543 or SHP-1 Y566 mutants 
using nucleofector based electroporation. After 48 hrs. the cells were starved overnight in EBM medium without serum. Sub-
sequently the cells were stimulated with VEGF for 5 min. Cell lysates were collected and expression of SHP-1 was confirmed. 
The same lysates were immunoblotted with antibodies against p-Tyr 1059 and p-Tyr 1175 of KDR. Total KDr and β-actin lev-
els were also determined. NIH Image quantitation data of (B) fold change in Tyr 1059 and (C) fold change in Tyr 1175 of KDR 
normalized with respect to total KDR. A representative image is shown the experiment was repeated three times.Journal of Molecular Signaling 2008, 3:8 http://www.jmolecularsignaling.com/content/3/1/8
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